Korean Guidelines for the Management of Dyslipidemia 5th

Committee of Clinical Practice Guideline of the Korean Society of Lipid and Atherosclerosis



Korean Guidelines for the Management of Dyslipidemia 506




Contents

Criteria for the classification of dyslipidemia	3
Major risk factors of atherosclerotic cardiovascular disease other than LDL-C	4
Recommendations for treatment goals of LDL-C and non-HDL-C	5
Treatment strategies according to risk categories and LDL-C	6
Dietary recommendation	7
Exercise prescription for patients with dyslipidemia	8
Evidence-guided approach algorithm of dyslipidemia treatment	9
Secondary causes of hypercholesterolemia or hypertriglyceridemia	10
Lipid-lowering efficacy and pharmacologic characteristics of statins	11
Summary of statin use	12
LDL-C lowering effect of statins in Koreans	13
Dutch lipid clinic network criteria for familial hypercholesterolemia	14
Simon Broome diagnostic criteria for familial hypercholesterolemia	15

Criteria for the classification of dyslipidemia




Unit: mg/dL



Major risk factors of atherosclerotic cardiovascular disease other than LDL-C¹⁾





1) High HDL cholesterol level (≥ 60 mg/dL) is considered as a protective factor, and one factor is excluded from the total number of risk factors.

LDL-C, low-density lipoprotein cholesterol ; HDL-C, high-density lipoprotein cholesterol.

Recommendations for treatment goals of LDL-C and non-HDL-C



Risk category	LDL-C (mg/dL)	non-HDL-C (mg/dL)
Coronary artery disease ^{1)*}	< 55	< 85
Atherosclerotic stroke and transient ischemic attack* Carotid artery disease* Peripheral artery disease* Abdominal aortic aneurysm* Diabetes mellitus (duration ≥ 10 years or major risk factor ⁺ or target organ damage) ²⁾	< 70	< 100
Diabetes mellitus (duration < 10 years and no major risk factors ⁺)	< 100	< 130
Moderate risk (major risk factors [†] ≥ 2)	< 130	< 160
Low risk (major risk factors [†] ≤ 1)	< 160	< 190

*It is also recommended to reduce LDL-C by \geq 50% from the baseline level.

[†]Age (men \geq 45 years, women \geq 55 years), family history of premature ASCVD, hypertension, smoking, and low HDL-C level (< 40 mg/dL).

1) In patient with acute myocardial infarction, statin is recommended irrespective of LDL-C level.

2) In diabetes mellitus with target organ damage (albuminuria, CKD [eGFR <60 mL/min/1.73m²], retinopathy, neuropathy, left ventricular hypertrophy) or major risk factors⁺ ≥ 3: target LDL-C < 55 mg/dL (optional)</p>

LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; ASCVD, atherosclerotic cardiovascular disease; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate.

Treatment strategies according to risk categories and LDL-C

Risk category	LDL-C (mg/dL)					
Misk outcyory	<55	55-69	70-99	100-129	130-159	≥ 160
Coronary artery disease ^{1)*}	Lifestyle modification and cosider drug	Lifestyle modification and concomitant drug internvention				
Atherosclerotic stroke and transient ischemic attack* Carotid artery disease* Peripheral artery disease* Abdominal arotic aneurysm* Diabetest mellitus (duration ≥ 10 years or major risk factor [†] or target organ damage) ²	Lifestyle modification	Lifestyle modification and cosider drug	Lifestyle modification and concomitant drug internvention	Lifestyle modification and concomitant drug internvention	Lifestyle modification and concomitant drug internvention	Lifestyle modification and concomitant drug internvention
Diabetes mellitus (duration < 10 years and no major risk factors [†])	Lifestyle modification	Lifestyle modification	Lifestyle modification and cosider drug	Lifestyle modification and concomitant drug internvention	Lifestyle modification and concomitant drug internvention	Lifestyle modification and concomitant drug internvention
Moderate risk ³⁾ (major risk factors [†] ≥ 2)	Lifestyle modification	Lifestyle modification	Lifestyle modification	Lifestyle modification and cosider drug	Lifestyle modification and concomitant drug internvention	Lifestyle modification and concomitant drug internvention
Low risk³) (major risk factors [†] ≤ 1)	Lifestyle modification	Lifestyle modification	Lifestyle modification	Lifestyle modification	Lifestyle modification and cosider drug	Lifestyle modification and concomitant drug internvention

*It is also recommended to reduce LDL-C by \geq 50% from the baseline level.

[†]Age (men \geq 45 years, women \geq 55 years), family history of premature ASCVD, hypertension, smoking, and low HDL-C level (< 40 mg/dL).

1) In patient with acute myocardial infarction, statin is recommended irrespective of LDL-C level.


2) In diabetic patients with target organ damage (albuminuria, CKD [eGFR <60 mL/min/1.73m²], retinopathy, neuropathy, left ventricular hypertrophy) or major risk factors[†] ≥ 3 (optional).

3) In groups with moderate and low risk, statin is considered when LDL-C is consistently high even after several weeks or months of lifestyle modification.

LDL-C, low-density lipoprotein cholesterol.

Dietary recommendation





Consume energy intake to maintain a healthy weight

Consume a healthy dietary pattern with a focus on whole grains, legumes, vegetables, and fish



Consume whole grains as a staple food



Consume plenty of vegetables



Consume fish, lean meat, or legumes rather than red and processed meat



Consume fresh fruits

Exercise prescription for patients with dyslipidemia




	Aerobic exericse	Resistance exercise	Stretching exercise	
Frequency	5 or more days a week to maximize calorie consumption	2-3 days a week	2-3 days or more a week	
Intensity	Moderate to high intensity, 40-75% of heart rate reserve ^{1,2)}	Moderate (50-69% of 1 RM ³⁾) to high (70-85% of 1 RM ³⁾) intensity for muscle strengthening	To the extent that the stretched area feels tight or slightly uncomfortable	
Duration	30-60 minutes a day (50-60 minutes a day for weight reduction)	For muscle strength improvement: 2-4 sets, 8-12 reps; for muscle endurance improvement: 2 sets or less, 12-20 reps	10-30 seconds, 2-4 reps	
Example	Continuous and rhythmic activities that use the large muscles (walking, cycling, swimming, etc.)	Use of resistance exercise equipment, full-body resistance training, free weight exercise, etc.	Static and dynamic stretching exercise	

1) Heart rate reserve = maximal heart rate - resting heart rate

2) How to calculate target heart rate = (220-age-resting heart rate) x exercise intensity (0.40~0.75) + resting heart rate


3) 1 RM (repetition maximum) = intensity/weight that can be performed once with the maximum effort of the individual

Evidence-guided approach algorithm of dyslipidemia treatment



Secondary causes of hypercholesterolemia or hypertriglyceridemia





Lipid-lowering efficacy and pharmacologic characteristics of statins



		Lovastatin	Pravastatin	Simvastatin	Atorvastatin	Fluvastatin	Rosuvastatin	Pitavastatin
Daily d (mg		20~40	10~40 ¹⁾	20~40	10~80	20~80	5~20 ²⁾	1~4
	24~28	20	20			40		1
LDL-C	30~36	40	40	20	10	80		2
reduction (%)	39~45	80		40	20		5~10	4
	46~52				40~80		20	
Metabo	olism	СҮРЗА4	Sulfonation	СҮРЗА4	СҮРЗА4	CYP2C9	CYP2C9	Glucuronidation (Partial CYP2C9)
Protein b (%)	Ŭ	> 95	43~67	95~98	98	98	88	> 99
Half-lif	e (h)	2~4	2~3	1~3	13~30	0.5~3	19	12
Hydroph	nilicity	-	+	-	-	-	+	-
Elimina	ation	Hepatobiliary	Hepatobiliary	Hepatobiliary	Hepatobiliary	Hepatobiliary	Hepatobiliary	Hepatobiliary
Renal elim fraction		10	20	13	< 2	< 6	28	15

1) 40~80 mg in Caucasian countries

2) 5~40 mg in Caucasian countries


Summary of statin use



	Statin: HMG-CoA reductase inhibitor			
	Lovastatin	20-80 mg once daily, take with dinner		
	Pravastatin	10-40 mg once daily, more effective to take it in the evening		
	Simvastatin	20-40 mg once daily, more effective to take it in the evening		
Dosing	Fluvastatin	20-80 mg once daily, more effective to take it in the evening		
	Atorvastatin	10-80 mg once daily, not significantly affected by the time taken		
	Rosuvastatin	5-20 mg once daily, not significantly affected by the time taken		
Pitavastatir		1-4 mg once daily, not significantly affected by the time taken		
Monitoring		Lipid profiles, liver function test and muscle enzyme (in case of unexplained myalgia or muscle weakness)		
Adverse effect		Dyspepsia, epigastric soreness, abdominal pain, hepatotoxicity, myopathy and diabetes mellitus		
Contraindication		It is absolutely contraindicated in pregnant or lactating women and active or chronic liver disease. It is relatively contraindicated when co-administered with other drugs such as cyclosporin, macrolide antibiotics, antifungals, and cytochrome P-450 inhibitors.		

LDL-C lowering effect of statins in Koreans





Dutch lipid clinic network criteria for familial hypercholesterolemia



	Criteria	Points
1) Family history	1st-degree relative with known premature (men < 55 years; women < 60 years) coronary or vascular disease, or 1st-degree relative with known LDL-C > 95th percentile	1
motory	1st-degree relative with tendinous xanthoma and/or arcus cornealis, or children < 18 years with LDL-C > 95th percentile	2
2) Clinical	Patient with premature CAD	2
history	Patient with premature cerebral or peripheral vascular disease	1
3) Physical	Tendon xanthoma	6
examination	Arcus cornealis at age <45 years	4
	> 8.5 mmol/L (325 mg/dL)	8
4) LDL-C (without treatment)	6.5-8.4 mmol/L (251-325 mg/dL)	5
	5.0-6.4 mmol/L (191-250 mg/dL)	3
	4.0-4.9 mmol/L (155-190 mg/dL)	1
5) DNA analysis	Functional mutation in the LDLR, APOB, or PCSK9 genes	8

Choose only one score per group, the highest applicable, diagnosis is based on the total number of points 'definite' FH: \geq 9 points / 'probable' FH: 6-8 points / 'possible' FH: 3-5 points

Simon Broome diagnostic criteria for familial hypercholesterolemia



Definite FH	Cholesterol criteria : < 16 years: total cholesterol > 260 mg/dL or LDL-C > 155 mg/dL ≥ 16 years: total cholesterol > 290 mg/dL or LDL-C > 190 mg/dL Plus at least one of the two: 1. Tendon xanthomas in patient, or in first- ¹⁾ or in second-degree ²⁾ relative 2. DNA-based evidence of an <i>LDLR</i> mutation, familial defective apoB-100, or a PCSK9 mutation
Possible FH	Cholesterol criteria : < 16 years: total cholesterol > 260 mg/dL or LDL-C > 155 mg/dL ≥ 16 years: total cholesterol > 290 mg/dL or LDL-C > 190 mg/dL Plus at least one of the two: 1. Family history of myocardial infarction : aged ≤ 60 years in first-degree ¹⁾ relative or aged ≤ 50 years in second-degree ²⁾ relative 2. Family history of raised total cholesterol : > 290 mg/dL in adult first- or second-degree relative or > 260 mg/dL in child, brother or sister aged < 16 years

1) First-degree relative: parents, siblings or children

2) Second-degree relative: grandparents, siblings of parents

FH, familial hypercholesterolemia ; LDL-C, low-density lipoprotein cholesterol ; LDL-R, low-density lipoprotein receptor ; apoB, apolipoprotein B.

Board of Directors

President

Vice-president

- Chairman
- Secretary General
- Treasurer

Director

Planning Committee Scientific Program Committee **Publication Committee Public Relations Committee** International Liaison Committee Insurance and Legislation Committee **Education Committee Clinical Practice Guideline Committee Clinic Research Committee Basic Research Committee Food and Nutrition Committee** Without Portfolio

Auditor

Seoul National University Seoul National University Donghoon Choi Yonsei University Yonsei University

Korea University

Myung-A Kim

Jae Bum Kim

Chul Sik Kim

Soon Jun Hong

Dae Jung Kim

Sang-Hak Lee

In-Kyung Jeong

Sung Hee Choi

Hyun Jae Kang

Byung Jin Kim

Sang-Hyun Kim

Sungha Park

Ung Kim

Young Mi Park

Min-Jeong Shin

Kee Ho Song

Goo Taeg Oh

Sung Rae Kim

Seonghoon Choi

Young Joon Hong

Jaetaek Kim

Ajou University Yonsei University Chung-Ang University Kyung Hee University Seoul National University Seoul National University Sungkvunkwan University Seoul National University Yonsei University Ewha Womans University Korea Universitv Yeungnam University Konkuk University Hallvm University Chonnam National University Ewha Womans University The Catholic University of Korea

Members

Byung Jin Kim Eu Jeong Ku Jae Hyeon Kim Ji Hyun Kim Hyeon Chang Kim Jin Oh Na Min Kyong Moon Kwang-Yeol Park Jae Hyoung Park Jae Hyun Bae Jang Won Son Kee Ho Song SuJin Song Aram Yang Ye Seul Yang Han Mo Yang Mi Sun Oh Hoyoun Won Tae-Hyun Yoo Sang-Hak Lee Eun-Jung Rhee Chan Joo Lee Jeong Hyun Lim Suk Chon Sae Young Jae Sang-Ho Jo Iksung Cho SeongHoon Choi Su-Yeon Choi Keun-Sik Hong Soon Jun Hong Soon-Cheol Hong

Sungkyunkwan University Chungbuk National University Sungkyunkwan University Dongguk University Yonsei University Korea University Seoul National University Chung-Ang University Korea University Korea University The Catholic University of Korea Konkuk University Hannam University Sungkyunkwan University The Catholic University of Korea Seoul National University Hallym University Chung-Ang University Yonsei University Yonsei University Sungkyunkwan University Yonsei University Seoul National University Kyung Hee University University of Seoul Hallym University Yonsei University Hallym University Seoul National University Inje University Korea University Korea University

Committee of Clinical Practice Guideline

Director Secretary Sang-Hyun Kim Seoul National University Hack-Lyoung Kim Seoul National University



www.lipid.or.kr